The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women.
ABSTRACT In 32 controlled trials of calcium supplementation (700-2000 mg) in 3,169 postmenopausal women, mean bone loss in the controls was -1.07% p.a. and in the treated subjects -0.27% p.a. (P for difference <0.001). The effect was similar at all measured sites and at all doses of 700 mg or more but became weaker after 4 years.
We have reviewed 32 trials of calcium supplementation in 3,169 postmenopausal women.
We found 24 publications reporting 32 controlled trials lasting at least 1 year, which provided annual percentage changes in bone mass or density at one or more sites in the calcium-treated and control subjects.
The median calcium supplement was 1,000 mg, median duration of the trials 2 years and total number of sites measured 79. The average of the mean rates of change in bone mass or density was -1.07% p.a. (P < 0.001) in the controls and -0.27% p.a. (ns) in the treated subjects (P for difference < 0.001). The effect of calcium was much the same at all measured sites (forearm/hand, proximal femur, spine, and total body and others). Supplements of less than 700 mg were not effective, but there was no significant beneficial effect of higher doses. There was significantly faster bone loss at total calcium intakes below 1,150 mg than on intakes over 1,350 mg. The effect of calcium appeared to be lost after 4 years of treatment.
Calcium supplementation of about 1,000 mg daily has a significant preventive effect on bone loss in postmenopausal women for at least 4 years.
- SourceAvailable from: James Dinicolantonio
[Show abstract] [Hide abstract]
- "Hence, nutritional insurance supplementation may provide the unexpected benefit of alleviating adverse health effects of excess phosphate. Moreover, ensuring good magnesium status may be beneficial for cardiovascular health while reducing risk for diabetes and colorectal cancer, and supplemental calcium may modestly aid maintenance of bone density           . Nonetheless, in the context of CKD, calcium salts, as opposed to non-calcium phosphate binders, have been associated with more coronary artery calcification, a greater risk for hypercalcemia , and a greater calcium-phosphate product; as one would suspect, PTH is better suppressed by supplemental calcium [108–110]. "
ABSTRACT: Increased fasting serum phosphate within the normal physiological range has been linked to increased cardiovascular risk in prospective epidemiology; increased production of fibroblast growth factor 23 (FGF23), and direct vascular effects of phosphate, may mediate this risk. Although dietary phosphate intake does not clearly influence fasting serum phosphate in those with normal renal function, increased phosphate intake can provoke an increase in FGF23, and in diurnal phosphate levels, and hence may adversely influence vascular health. Dietary phosphate absorption can be moderated by emphasizing plant-based dietary choices (which provide phosphate in less-bioavailable forms), avoidance of processed foods containing inorganic phosphate food additives, and by ingestion of phosphate-binder drugs, magnesium supplements, or niacin, which precipitate phosphate or suppress its gastrointestinal absorption. The propensity of dietary phosphate to promote vascular calcification may be opposed by optimal intakes of magnesium, vitamin K, and vitamin D; the latter should also counter the tendency of phosphate to elevate parathyroid hormone.Nutrition 01/2013; 30(7-8). DOI:10.1016/j.nut.2013.12.010 · 3.05 Impact Factor
Article: Calcium supplement and bone lossOsteoporosis International 10/2009; 20(12):2149; author reply 2151-3. DOI:10.1007/s00198-009-1073-0 · 4.17 Impact Factor
- Osteoporosis International 10/2009; 20(12):2147-8; author reply 2151-3. DOI:10.1007/s00198-009-1072-1 · 4.17 Impact Factor